Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2021 Publisher: Accord Healthcare Limited, Sage House, 319, Pinner Road, North Harrow, Middlesex, HA1 4HF, United Kingdom
Atrolak XL 50 mg prolonged-release tablets.
| Pharmaceutical Form |
|---|
|
Prolonged-release tablet. Peach colored, round shaped, biconvex film coated tablets, debossed with ‘Q50’ on one side and plain on the other. Note: Diameter of the tablet 11.2 ± 0.2 mm. |
Each 50 mg prolonged release tablet contains 50 mg quetiapine (as quetiapine fumarate).
Excipient(s) with known effect: 140.925 mg Lactose monohydrate per tablet
For the full list of excipients, see Section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Quetiapine |
Quetiapine is an atypical antipsychotic agent. Quetiapine and the active human plasma metabolite, norquetiapine interact with a broad range of neurotransmitter receptors. |
| List of Excipients |
|---|
|
Core: Lactose monohydrate Coating: Opadry II 85F540003 Pink contains: Poly (Vinyl alcohol) |
PVC/PVDC-Alu blister pack or OPA/Alu/PVC–Alu blister pack. Pack size of 6, 10, 20, 28, 30, 50, 60, 90 and 100 tablets per pack.
Not all pack sizes may be marketed.
Accord Healthcare Limited, Sage House, 319, Pinner Road, North Harrow, Middlesex, HA1 4HF, United Kingdom
PL 20075/0213
19/06/2013
| Drug | Countries | |
|---|---|---|
| ATROLAK | Spain, Poland, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
